跳转至内容
Merck
CN

SML1221

度他雄胺

≥98% (HPLC), 5α-reductase isoenzymes types 1 and 2 inhibitor, powder

别名:

17β-N-[2,5-双(三氟甲基)苯基]-氨基甲酰基-4-氮杂-5α-雄烷-1-烯-3-酮, (5α,17β)-N-[2,5-双(三氟甲基)苯基] -3-氧代-4-氮杂杂芳-1-烯-17-羧酰胺

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C27H30F6N2O2
化学文摘社编号:
164656-23-9
分子量:
528.53
UNSPSC Code:
51111800
PubChem Substance ID:
329825728
NACRES:
NA.77
MDL number:
MFCD00937869

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

度他雄胺, ≥98% (HPLC)

SMILES string

O=C1C=C[C@@]2(C)[C@](CC[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@@H]4C(NC5=CC(C(F)(F)F)=CC=C5C(F)(F)F)=O)([H])N1

InChI

1S/C27H30F6N2O2/c1-24-11-9-17-15(4-8-21-25(17,2)12-10-22(36)35-21)16(24)6-7-19(24)23(37)34-20-13-14(26(28,29)30)3-5-18(20)27(31,32)33/h3,5,10,12-13,15-17,19,21H,4,6-9,11H2,1-2H3,(H,34,37)(H,35,36)/t15-,16-,17-,19+,21+,24-,25+/m0/s1

InChI key

JWJOTENAMICLJG-QWBYCMEYSA-N

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D +18 to +24°, c = 1 in chloroform-d

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

Quality Level

100

Gene Information

human ... SRD5A1(6715), SRD5A2(6716), SRD5A3(79644)

正在寻找类似产品? 访问 产品对比指南

相关类别

Biochem/physiol Actions

度他雄胺是1型和2型5α-还原酶同工酶的有效双重抑制剂 (IC50 = 6 nM 5-AR1; 7 nM 5-AR2)。度他雄胺可阻断睾丸激素向二氢睾丸酮的转化，并在临床上用于治疗良性前列腺增生 (BPH)。

pictograms

Health hazard
GHS08

signalword

Danger

Hazard Classifications

Carc. 2 - Repr. 1B

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000452844
0000452844
0000416517
0000416517
0000274023

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

5α-Reductase Inhibition Coupled with Short Off Cycles Increases Survival in the LNCaP Xenograft Prostate Tumor Model on Intermittent Androgen Deprivation Therapy.
Pascal, L.E., et al.
The Journal of Urology, Oct 31 (2014)
Sungsin Jo et al.
Arthritis research & therapy, 22(1), 121-121 (2020-05-26)
Ankylosing spondylitis (AS) is characteristically male-predominant, and progressive spinal ankylosis affects male patients more severely; however, the hormonal effects in males with AS are poorly understood. In the present study, the regulatory effects of dutasteride, a 5-α reductase inhibitor that
Akira Tsujimura et al.
Urology, 85(1), 274-274 (2014-12-03)
To evaluate histologic change in human prostate samples treated with dutasteride and to elucidate direct effects of dutasteride on human prostate tissue, the present study was conducted by using a xenograft model with improved severe combined immunodeficient (super-SCID) mice, although
Christopher Wu et al.
Expert opinion on pharmacotherapy, 14(10), 1399-1408 (2013-06-12)
Benign prostatic hyperplasia (BPH) is an age-related phenomenon associated with prostatic enlargement and bladder outlet obstruction that can cause significant lower urinary tract symptoms that greatly affect quality of life. Dutasteride is a selective inhibitor of type 1 and type

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持